Status:
UNKNOWN
Pharmacogenetic Effect on the Pharmacodynamics of Glibenclamide
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Diabetes
Eligibility:
All Genders
20-90 years
Brief Summary
Glibenclamide is metabolized by the hepatic enzyme P450 CYP2C9 to less active form. Polymorphism of this enzyme demonstrated clinical significance when examined on other drugs from the sulfonylurea dr...
Eligibility Criteria
Inclusion
- Tx with metformin and glibenclamide
Exclusion
- Tx which affecting the P450 2C9 action
- Renal failure
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01242137
Start Date
October 1 2009
Last Update
November 16 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofe Medical Center
Beer Yakov, Israel